Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
News for 89bio, Inc. (ETNB) centers on its role as a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases, as well as its corporate transition following its acquisition by Roche. Company press releases and SEC reports highlight pegozafermin, a fibroblast growth factor 21 (FGF21) analog engineered with glycoPEGylated technology, as its lead product candidate in Phase 3 development for metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis and severe hypertriglyceridemia (SHTG).
Visitors to this ETNB news page can review historical announcements about 89bio’s clinical programs, including updates on the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in MASH and the ENTRUST Phase 3 trial in SHTG. Releases describe trial designs, planned topline data timing, and the company’s expectations regarding potential regulatory pathways, as well as operational items such as construction of a commercial-scale production facility for pegozafermin.
The news flow also covers corporate and capital markets activity. This includes inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), participation in major healthcare and biopharma investor conferences, and quarterly financial updates that discuss research and development spending and general and administrative expenses in the context of advancing the Phase 3 programs.
A key development in the ETNB news record is the announcement of an Agreement and Plan of Merger with Roche Holdings, Inc., followed by the commencement and completion of a tender offer. Related communications describe the cash consideration, the structure of non-tradeable contingent value rights (CVRs) tied to pegozafermin milestones, and the subsequent delisting of ETNB from The Nasdaq Global Market as 89bio became a wholly owned subsidiary of Roche. Investors and researchers can use this page as an archive of 89bio’s historical news, from clinical milestones to the closing of the Roche transaction.
89bio, a clinical-stage biopharmaceutical company focused on liver and cardio-metabolic diseases, announced that CEO Rohan Palekar will present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 11:30 AM ET. The presentation will be available via live and archived webcast on the company’s website. 89bio's lead product, BIO89-100, targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company is headquartered in San Francisco with operations in Herzliya, Israel.
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that CEO Rohan Palekar will present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 11:30 AM ET. The event will be available via live and archived webcast on the company's website. 89bio is focused on developing innovative therapies for liver and cardio-metabolic diseases, with its lead product candidate, BIO89-100, targeting NASH and severe hypertriglyceridemia. The company is based in San Francisco and has operations in Israel.
89bio, Inc. (Nasdaq: ETNB) has announced the pricing of an upsized public offering of 3,300,000 shares at $28.00 each, aiming for gross proceeds of approximately $84.7 million. The offering consists of 3,025,000 shares from 89bio and 275,000 shares from a selling stockholder. Additionally, the underwriters have a 30-day option to purchase up to 495,000 additional shares. The offering is expected to close on September 21, 2020, pending customary conditions. BofA Securities, SVB Leerink, and RBC Capital Markets are leading the offering.
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced a public offering of 3,000,000 shares of common stock. This includes 2,700,000 shares from the company and 300,000 shares from stockholders. There is also an option for underwriters to purchase an additional 450,000 shares. The proceeds will support the BIO89-100 programs targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The offering depends on market conditions and a registration statement that has yet to become effective.
89bio (Nasdaq: ETNB) announced positive topline results from its Phase 1b/2a trial of BIO89-100, an investigational FGF21 analog for nonalcoholic steatohepatitis (NASH). All dose groups achieved significant liver fat reductions, with up to 70% versus placebo. Notably, 88% of subjects had at least a 30% reduction in liver fat. The treatment demonstrated a strong safety profile, with low adverse event incidence. BIO89-100 is positioned as a promising therapy for NASH, with further trials planned in 2021.
89bio, Inc. (Nasdaq: ETNB) announced plans to share topline safety, tolerability, and efficacy data from its Phase 1b/2a study of BIO89-100 for NASH on September 14, 2020. The presentation will take place during a pre-market conference call at 8:30 AM PT, featuring a live webcast accessible through the company’s website. BIO89-100 is a glycoPEGylated analog of FGF21 aimed at treating NASH and severe hypertriglyceridemia. Investors can find further information on the event and future developments on the company’s investor relations page.
89bio, Inc. (Nasdaq: ETNB) announced the initiation of a Phase 2 trial for BIO89-100, targeting severe hypertriglyceridemia (SHTG), with enrollment of approximately 90 participants. This double-blind, placebo-controlled study seeks to evaluate the safety and efficacy of BIO89-100, a glycoPEGylated analog of FGF21. The primary endpoint focuses on reducing fasting triglycerides, while secondary endpoints include effects on other lipids and liver fat reduction. This study builds on promising early clinical data suggesting significant metabolic benefits, addressing a crucial need for alternative therapies.
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced CEO Rohan Palekar's participation in two upcoming conferences. He will speak at the BTIG Virtual Biotechnology Conference on August 10, 2020, at 11:30 AM ET, and at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 10:00 AM ET. The company is developing therapies for liver and cardio-metabolic diseases, including its lead candidate, BIO89-100, targeted for NASH treatment. Webcasts will be available on their website after the events.
89bio, Inc. (Nasdaq: ETNB) has completed its upsized public offering of 3,047,040 shares of common stock, including the underwriters' additional purchase option. The offering price was $27.50 per share, generating approximately $83.8 million in gross proceeds, before expenses. This fundraise will support the development of innovative therapies for liver and cardio-metabolic diseases, particularly their lead candidate, BIO89-100, which is currently in clinical trials for NASH and NAFLD. The offering was led by BofA Securities, SVB Leerink, and RBC Capital Markets.
89bio, a clinical-stage biopharmaceutical company, announced an upsized public offering of 2,649,600 shares at $27.50 each, totaling approximately $72.9 million in gross proceeds. The underwriters also have a 30-day option to buy an additional 397,440 shares. The offering is expected to close on July 10, 2020. Major financial institutions, including BofA Securities and SVB Leerink, are managing the offering. The proceeds are aimed at advancing 89bio’s development of innovative therapies for liver and cardio-metabolic diseases, specifically targeting NASH and SHTG.